Study	Reason for exclusion
Brinson 2007	ALLOCATION: No concealment of allocation
De La Cruz 2007	ALLOCATION: No concealment of allocation, no blinding, no randomisation
Durland 2005	ALLOCATION: No control group, therefore no concealment of allocation
Garduno‐Anaya 2005	ALLOCATION: Patients were randomised into 2 groups. The sequence generation and concealment of allocation were not described. PARTICIPANTS: AAO‐HNS criteria were used to diagnose Ménière's disease INTERVENTION: Intratympanic application of dexamethasone for the treatment of Ménière's disease, which is studied in a separate Cochrane review (Phillips 2011)
Heatley 1990	ALLOCATION: Non‐randomised study
Rask‐Andersen 2005	ALLOCATION: The sequence generation and allocation concealment were not described PARTICIPANTS: Patients with unilateral Ménière's disease. The AAO‐HNS criteria were not used. INTERVENTION: Intratympanic application of latanoprost for the treatment of Ménière's disease will be studied in a separate Cochrane review
Silverstein 1998	ALLOCATION: Randomised PARTICIPANTS: Included patients with Ménière's disease and possible Ménière's disease INTERVENTIONS: Patients received 3 consecutive daily administrations of intratympanic dexamethasone or placebo. Intratympanic application of dexamethasone for the treatment of Ménière's disease is studied in a separate Cochrane review (Phillips 2011).
Teggi 2008	ALLOCATION: Randomised PARTICIPANTS: Patients with Ménière's disease according to the AAO‐HNS criteria INTERVENTION: Low‐level laser therapy (LLLT) versus betahistine. LLLT is not considered to be a surgical intervention